
17. Fuchikami C, Murakami K, Tajima K, Homan J, Kosugi K, Kuramoto K, et al. A comparison of vasodila-
tion mode among selexipag (NS-304; [2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-
(methylsulfonyl)acetamide]), its active metabolite MRE-269 and various prostacyclin receptor agonists
in rat, porcine and human pulmonary arteries. Eur J Pharmacol. 2017; 795: 75–83. https://doi.org/10.
1016/j.ejphar.2016.11.057 PMID: 27919660
18. Abe K, Toba M, Alzoubi A, Ito M, Fagan KA, Cool CD, et al. Formation of plexiform lesions in experimen-
tal severe pulmonary arterial hypertension. Circulation. 2010; 121: 2747–2754. https://doi.org/10.1161/
CIRCULATIONAHA.109.927681 PMID: 20547927
19. Oka M, Homma N, Taraseviciene-Stewart L, Morris KG, Kraskauskas D, Burns N, et al. Rho kinase-
mediated vasoconstriction is important in severe occlusive pulmonary arterial hypertension in rats. Circ
Res. 2007; 100: 923–929. https://doi.org/10.1161/01.RES.0000261658.12024.18 PMID: 17332430
20. Liu P, Yan S, Chen M, Chen A, Yao D, Xu X, et al. Effects of baicalin on collagen and collagen expres-
sion in pulmonary arteries of rats with hypoxic pulmonary hypertension. Int J Mol Med. 2015; 35: 901–
908. https://doi.org/10.3892/ijmm.2015.2110 PMID: 25716558
21. Orellana R, Garcı
´
a-Solares J, Donnez J, van Kerk O, Dolmans MM, Donnez O. Important role of collec-
tive cell migration and nerve fiber density in the development of deep nodular endometriosis. Fertil
Steril. 2017; 107: 987–995.e5. https://doi.org/10.1016/j.fertnstert.2017.01.005 PMID: 28238494
22. Nakahata N. Thromboxane A2: physiology/pathophysiology, cellular signal transduction and pharma-
cology. Pharmacol Ther. 2008; 118: 18–35. https://doi.org/10.1016/j.pharmthera.2008.01.001 PMID:
18374420
23. Christman BW, Mcpherson CD, Newman JH, King GA, Bernard GR, Groves BM, et al. An imbalance
between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl
J Med. 1992; 327: 70–75. https://doi.org/10.1056/NEJM199207093270202 PMID: 1603138
24. Yamamoto K, Ebina S, Nakanishi H, Nakahata N. Thromboxane A2 receptor-mediated signal transduc-
tion in rabbit aortic smooth muscle cells. Gen Pharmacol. 1995; 26: 1489–1498. https://doi.org/10.
1016/0306-3623(95)00025-9 PMID: 8690235
25. Badejo AM, Dhaliwal JS, Casey DB, Gallen TB, Greco AJ, Kadowitz PJ. Analysis of pulmonary vasodi-
lator responses to the Rho-kinase inhibitor fasudil in the anesthetized rat. Am J Physiol—Lung Cell Mol
Physiol. 2008; 295: 828–836. https://doi.org/10.1152/ajplung.00042.2008 PMID: 18689606
26. Pankey EA, Bhartiya M, Badejo AM, Haider U, Stasch JP, Murthy SN, et al. Pulmonary and systemic
vasodilator responses to the soluble guanylyl cyclase activator, BAY 60–2770, are not dependent on
endogenous nitric oxide or reduced heme. Am J Physiol—Hear Circ Physiol. 2011; 300: 792–802.
https://doi.org/10.1152/ajpheart.00953.2010 PMID: 21217076
27. Kuwano K, Hashino A, Asaki T, Hamamoto T, Yamada T, Okubo K, et al. 2-{4-[(5,6-Diphenylpyrazin-2-
yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide (NS-304), an orally available and long-acting
prostacyclin receptor agonist prodrug. J Pharmacol Exp Ther. 2007; 322: 1181–1188. https://doi.org/
10.1124/jpet.107.124248 PMID: 17545310
28. Stacher E, Graham BB, Hunt JM, Gandjeva A, Groshong SD, McLaughlin VV., et al. Modern age
pathology of pulmonary arterial hypertension. Am J Respir Crit Care Med. 2012; 186: 261–272. https://
doi.org/10.1164/rccm.201201-0164OC PMID: 22679007
29. Yi ES, Kim H, Ahn H, Strother J, Morris T, Masliah E, et al. Distribution of obstructive intimal lesions and
their cellular phenotypes in chronic pulmonary hypertension: A morphometric and immunohistochemi-
cal study. Am J Respir Crit Care Med. 2000; 162: 1577–1586. https://doi.org/10.1164/ajrccm.162.4.
9912131 PMID: 11029379
30. Kuwano K, Hashino A, Noda K, Kosugi K, Kuwabara K. A long-acting and highly selective prostacyclin
receptor agonist prodrug, 2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)
acetamide (NS-304), ameliorates rat pulmonary hypertension with unique relaxant responses of its
active form, {4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}acetic Acid (MRE-269), on rat pul-
monary artery. J Pharmacol Exp Ther. 2008; 326: 691–699. https://doi.org/10.1124/jpet.108.138305
PMID: 18552131
31. Nakamura A, Yamada T, Asaki T. Synthesis and evaluation of N-acylsulfonamide and N-acylsulfony-
lurea prodrugs of a prostacyclin receptor agonist. Bioorganic Med Chem. 2007; 15: 7720–7725. https://
doi.org/10.1016/j.bmc.2007.08.052 PMID: 17881233
32. Kato F, Sakao S, Takeuchi T, Suzuki T, Nishimura R, Yasuda T, et al. Endothelial cell-related autopha-
gic pathways in Sugen/hypoxia-exposed pulmonary arterial hypertensive rats. Am J Physiol—Lung Cell
Mol Physiol. 2017; 313: L899–L915. https://doi.org/10.1152/ajplung.00527.2016 PMID: 28798259
33. Kaufmann P, Okubo K, Bruderer S, Mant T, Yamada T, Dingemanse J, et al. Pharmacokinetics and tol-
erability of the novel oral prostacyclin IP receptor agonist selexipag. Am J Cardiovasc Drugs. 2015; 15:
195–203. https://doi.org/10.1007/s40256-015-0117-4 PMID: 25850750
Effects of selexipag on Sugen 5416/hypoxia PAH rats
PLOS ONE | https://doi.org/10.1371/journal.pone.0240692 October 15, 2020 19 / 20